Cancer therapeutics are becoming increasingly more expensive, yet more personalized. In this video, Cleveland Clinic oncologist Nathan Pennell, MD, discusses value-based effectiveness of new lung cancer therapies.

Dr. Pennell is a board certified medical oncologist who joined the staff of Cleveland Clinic's Taussig Cancer Center in 2008. He specializes in the treatment of thoracic malignancies with a focus on lung cancer, and was appointed Director of the TCI Lung Cancer Medical Oncology program in 2010. He is an Associate Professor of Medical Oncology at the Cleveland Clinic Lerner College.

Dr. Pennell's research interests include clinical trials using novel therapies, with a goal of facilitating the movement of new treatments from the laboratory to the clinic.